Experimental Acanthamoeba keratitis: I. Preliminary findings

D F P Larkin, D L Easty

Abstract
Experimental Acanthamoeba keratitis was induced in Wistar rats by intrastromal inoculation of Acanthamoeba polyphaga cysts. Keratitis developed in all corneas injected and was characterised by a diffuse granular opacity. The animals were examined for 70 days and a gradual reduction of keratitis was observed. Pathological sections showed liquefactive stromal necrosis and Acanthamoeba localised in deep stroma persisting to 70 days. A brisk inflammatory infiltrate of neutrophils and macrophages was seen in the early days of infection. Severity of keratitis was found to correlate with inflammatory activity in pathological sections. The uses of an animal model of Acanthamoeba keratitis are described.

Acanthamoeba is a genus of free-living protozoon with a ubiquitous distribution in nature. It has a life cycle of active trophozoite and dormant cyst stages. First isolated and described in 1913, it was not considered to have pathogenic potential until reported to cause fatal meningoencephalitis in animal inoculation experiments in 1959. Some years later, when suspected amoebic encephalitis was reported in humans, the similarity to Acanthamoeba infection induced experimentally was recognised and suggested the aetiological role of Acanthamoeba. The pathological features of human encephalitis are similar to those of experimental Acanthamoeba encephalitis in mice that the use of animal models for studying other forms of Acanthamoeba infection is clearly indicated.

After initial reports, Acanthamoeba infection of the cornea remained a rare disease until an association with contact lens wear was first recognised. Reports of cases have exponentially increased since that time, and a recent analysis identified 85% of affected patients as contact lens wearers. Acanthamoeba keratitis typically has an indolent but progressive course, with intense discomfort and stromal infiltration. Therapy of Acanthamoeba keratitis is difficult in all cases, with frequent failures of medical and surgical treatment and loss of the eye in some of these.

Even though the keratitis has become more common than the encephalitis, few laboratory in-vivo studies have been reported. Rabbit models have been developed, first by Font and colleagues. After subconjunctival administration of corticosteroid for four days the direct intrastromal injection of A polyphaga induced stromal keratitis and corneal ulceration. Some corneas were culture-positive at intervals, and encysted amoebae were observed in tissue on microscopy. A further rabbit model was reported by Lin and colleagues in which the effect of steroid administration was analysed. Badenoch et al reported a model in Porton rats in which induction of Acanthamoeba keratitis was dependent on coinoculation with bacteria.

In this study the Wistar rat was used as the experimental animal. The initial objective of the study was to induce reproducible disease similar to the human disease, for use in evaluation of immunopathology and therapeutic agents. So that the specific immune response to Acanthamoeba could be studied coinoculation with bacteria was avoided.

Materials and methods

Animals. Male Wistar rats weighing approximately 125 g were used. The corneas were examined prior to inoculation to exclude abnormality (Fig 1A). There were 24 rats in the infected group and six in the control group. All procedures were performed on the right eye.

Amoeba. All studies were performed with the Shinh strain of A polyphaga, a human corneal isolate (kindly provided by Mr S Kilvington, Public Health Laboratory, Bath). This had been frozen in liquid nitrogen and passed on to a Vero cell monolayer three times. An axenic suspension of 1 x 10⁵ amoebae/ml (90% cysts) was prepared in Page's amoeba saline.

Anaesthesia. Diazepam 0.25 mg and fentanyl 0.01 mg/fluanisone 0.3 mg were given by intramuscular injection, and one drop of preservative-free benoxinate was applied to the right eye.

Inoculation technique. The procedure was performed under an operating microscope (OPMI 1 FC, Carl Zeiss Ltd). Initially a half thickness linear blade incision was made approximately 2 mm from the centre of the cornea. With a microlitre syringe (Hamilton Bonaduz AG) and a sterile 30 G needle (Becton-Dickinson & Co.), the needle was advanced from the incision through the lamellae of the stroma to the centre of the cornea. 1 μl was injected into the stroma. Control animals received a mock inoculum of 1 μl of Page's saline; infection animals received a suspension of 1 x 10⁵ amoebae/ml (90% cysts) in Page's amoeba saline.

Clinical evaluation. Under fentanyl general anaesthesia the rats were examined with a slitlamp microscope on days 1, 3, 5 and 7 following inoculation and weekly thereafter until 70 days. Examination was by retroillumination, resulting in transillumination of the albino iris and the cornea. The oblique slit beam was used to illuminate lesser degrees of opacity. A clinical grading system was used to describe corneal opacity:

Grade 3: opacity visible on retroillumination, obscuring iris vessel detail.
Grade 2: opacity visible on retroillumination, but not sufficient to obscure iris vessels.

Grade 1: opacity visible only by oblique slit beam.

Grade 0: normal.

A mean opacity grade was calculated for the infected corneas on each examination day. Photographs were taken with the operating microscope with retroillumination of the cornea, 160 ASA tungsten film (Kodak Ektachrome) and automatic microscope.

On days 1, 3, 7, 14, 21, 28, 49, and 70 after inoculation two infected rats were killed by intraperitoneal injection of 60 mg pentobarbitone. Two control rats were killed on days 1, 3, and 7.

**Tissue processing.** The eye was enucleated and the cornea dissected from the globe and hemisected. One half of the cornea was fixed for 24 h in neutral buffered formaldehyde, embedded in wax, and 6 µm thickness sections cut with a microtome; the other half was either immediately frozen in liquid nitrogen or homogenised with a glass grinder for culture.

**Preparation of specific antibody.** Rabbit antiserum was prepared to the experimental strain of *A polyphaga* according to the method described by Warhurst. Briefly, a 2.5 kg New Zealand White rabbit was injected intramuscularly with 30 ml *A. polyphaga*/Freund's complete adjuvant and this was repeated at a three-week interval. This was followed by two 0.6 ml intravenous injections of formalinised *A. polyphaga* cysts at four and five weeks. After venepuncture at six weeks the antiserum titre was measured and found to be 1/1024. The serum was then affinity purified on a chromatography column using protein A-Sepharose (Sepharose CL-4B, Pharmacia, Uppsala, Sweden) to yield the IgG fraction.

**Staining of wax sections.** Sections were stained with haematoxylin and eosin or with rabbit anti-Acanthamoeba antibody. For the latter procedure sections were first incubated at room temperature with 1:5 normal swine serum (Dakopatts a/s) to block non-specific background staining; they were then incubated in sequence with rabbit anti-Acanthamoeba antibody at dilution 1:10 for 30 minutes, and peroxidase-conjugated swine anti-rabbit immunoglobulin (Dakopatts a/s) at dilution 1:50 for 30 minutes. Phosphate-buffered saline (PBS) was used for all dilutions, and sections were washed with PBS following each of these incubations. 3,3'-Diaminobenzidine (Sigma Chemical Co.) was the chromagen used to identify antibody binding, mixed with H₂O₂ in 0.1 M trometamol (Tris) buffer, giving a brown end-product; sections were incubated for three minutes and then washed in tap water for five minutes. Sections were counterstained with haematoxylin.

**Culture of corneas for Acanthamoeba.** Non-nutrient agar was set in each well of 25-well Petri plates. A lawn of live *Escherichia coli* was added to the agar surface in each well, and after 8 hours' incubation at 37°C the plates were ready for inoculation with tissue. Hemicorneas were homogenised in 150 µl of Page's saline with a glass grinder, 10 µl of the undiluted homogenate added to each well, and the plate sealed. Corneas
from control and infected eyes were cultured and observed by microscopy for seven days. If no growth was seen by seven days, the culture was deemed negative.

Results

Clinical Evaluation
The cloudy opacification observed immediately after injection of all corneas cleared completely in control rats before the first examination day 1. Reepithelialisation of the linear incision had also occurred by this time.

All rats inoculated with *Acanthamoeba* developed keratitis. Certain clinical features were consistently observed. Opacity was granular in character, with corneal thinning superficial to infiltrates apparent in animals with more longstanding keratitis. Minimal, if any, vascularisation and no corneal perforation was seen (Figs 1B, 1C, 1D). No epithelial disease and no signs of anterior uveitis such as nodular infiltrates or hypopyon were observed.

On days 1, 3, and 5 following inoculation grade 3 opacity was observed in almost all rats, maximal at the inoculation site. On day 7 corneal opacity was grade 3 in most rats but had diminished to grade 2 in some. On subsequent examinations a gradual reduction in mean grade of corneal opacity was found (Table I).

Examination of Pathological Sections
Haematoxylin and eosin (H-E) staining of infected corneas identified a marked inflammatory response of neutrophils and macrophages at the inoculation site on day 1 (Fig 2A). A distinction between *Acanthamoeba* and inflammatory cells was not possible by H-E stain but was facilitated by immunoperoxidase staining with anti-*Acanthamoeba* antibody (Fig 2B). Excystment of many amoebae (Fig 2C) and trophozoite migration from the inoculation site was seen by day 3. A more subdued and mixed inflammatory response was evident by this time, with lymphocytes and monocytes appearing among the neutrophils and macrophages seen on day 1. By day 7 trophozoites were seen throughout the cornea, though large numbers of cysts remained at the inoculation site. Marked stromal thinning was seen overlying the inoculation site in some corneas at day 14 (Fig 2E). Examination of corneas late in disease, from days 21 to 70, consistently revealed amoebae and inflammatory cells to be localised to the inoculation site, surrounded by eosinophilic material.

A gradually diminishing inflammatory response was seen in control corneas at 1, 3 and 7 days after mock inoculation (Fig 2F).

Culture of Cornea
Positive *Acanthamoeba* cultures resulted from infected corneas of all animals killed at days 1-49 inclusive. The homogenised corneas of the rat killed at day 70 and all control rats were culture-negative.

Discussion
The value of an animal model of *Acanthamoeba* keratitis is attested to by the gravity and increasing prevalence of clinical disease in humans. Study of *Acanthamoeba* keratitis in an animal model allows control of many of the variable factors involved in human disease. In

<table>
<thead>
<tr>
<th>Day</th>
<th>Number of rats examined</th>
<th>Mean grade of keratitis (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>24</td>
<td>2.72 (0.60)</td>
</tr>
<tr>
<td>3</td>
<td>22</td>
<td>2.76 (0.61)</td>
</tr>
<tr>
<td>5</td>
<td>20</td>
<td>2.77 (0.59)</td>
</tr>
<tr>
<td>7</td>
<td>18</td>
<td>2.42 (0.79)</td>
</tr>
<tr>
<td>10</td>
<td>16</td>
<td>1.75 (0.65)</td>
</tr>
<tr>
<td>14</td>
<td>14</td>
<td>1.71 (0.76)</td>
</tr>
<tr>
<td>21</td>
<td>12</td>
<td>1.93 (0.83)</td>
</tr>
<tr>
<td>28</td>
<td>10</td>
<td>1.79 (0.49)</td>
</tr>
<tr>
<td>42</td>
<td>8</td>
<td>1.50 (0.58)</td>
</tr>
<tr>
<td>70</td>
<td>6</td>
<td></td>
</tr>
</tbody>
</table>
554

Figure 2C  Day 1: excysting Acanthamoeba (thin arrow) at the site of the linear blade incision, indicated by epithelial derangement (wide arrow). Anti-Acanthamoeba antibody, ×300.)

Figure 2D  Day 7: cyst (large arrow) and trophoaste (small arrow), each being killed by several inflammatory cells (Anti-Acanthamoeba antibody, ×760.)

Figure 2E  Day 14: marked thinning of corneal stroma overlying Acanthamoeba cysts which are in deep stroma. These have not migrated and rest on Descemet’s membrane. (Anti-Acanthamoeba antibody, ×140.)

Figure 2F  Day 3: control cornea showing low-grade inflammation at inoculation site (arrow). (Anti-Acanthamoeba antibody, ×190.)

particular, the clinical features of established stromal infection may be analysed, pathological study of tissue undertaken, and, in an established model, treatments evaluated. The most appropriate treatment for Acanthamoeba keratitis has yet to be decided: insufficient correlation between in-vitro drug sensitivity tests and clinical response renders it difficult to evaluate new drugs.

In this study Acanthamoeba keratitis was induced by inoculation of organisms directly into the corneal stroma. Therefore this model does not address questions on the means by which infection arises, but what follows once a large number of cysts reach the stroma. Reproducible keratitis developed in all rat corneas inoculated with 1 μl of a suspension of Acanthamoeba at a concentration of 1 x 10⁶/ml. Because in clinical practice such an inoculum of cysts would be very unlikely, this may indicate that Acanthamoeba are less infective for the rat cornea than the human. Certain clinical features mimic those observed in human infection, such as minimal corneal vascularisation and diffuse granular opacity formation rather than formation of an abscess. Although acute fulminating infection was not induced, the clinical course of the experimental keratitis is shorter than the human disease, which may remain active for several months. This might be due to differences in rat and human susceptibility to infection. In general, clinical inflammation correlated with histopathological indices of inflammation rather than presence of amoebae as such. In accordance with the report of Font et al.⁷ cysts seemed more resistant to destruction than trophozoites.

Most human specimens on which histopathological descriptions are available originate from corneal transplantation and accordingly describe late stages of the disease, probably modified by drug therapy. Nevertheless, available reports describe changes similar to those described in this report. Disruption and necrosis of stromal lamellae and invasion by amoebae of deep stroma to Descemet’s membrane are observed with infiltrates of neutrophils; in some cases there is an added lymphocyte and plasma cell component.⁸⁻¹⁰ However, Acanthamoeba can be seen in tissue relatively free of inflammation.²⁻⁸ Initial conclusions from this study indicate that reproducible keratitis of short clinical duration can be induced by intrastromal injection of axenic Acanthamoeba cysts without the need for concomitant immunosuppression by corticosteroid⁹⁻¹⁰ or coinoculation with bacteria.¹⁰ Thus the rat provides a useful model for investigating the pathology of Acanthamoeba keratitis. Further sequential studies are in progress to
characterise the cellular composition of the immune response to *Acanthamoeba*. This model will provide improved understanding of *Acanthamoeba*-host interactions and ultimately will allow evaluation of specific antimicrobial drugs with and without corticosteroid.

This study was supported in part by grants from Alcon Laboratories Ltd, the British Council for the Prevention of Blindness, and the South-Western Regional Health Authority.

The authors are indebted to Simon Kilvington, BSc, for initially providing *Acanthamoeba* cysts and assisting with preparation an anti-*Acanthamoeba* antibody; and to Ian Williams for assistance with the preparation of tissue sections.

Experimental Acanthamoeba keratitis: I. Preliminary findings.

D F Larkin and D L Easty

Br J Ophthalmo1 1990 74: 551-555
doi: 10.1136/bjo.74.9.551

Updated information and services can be found at:
http://bjo.bmj.com/content/74/9/551

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/